Immunogenicity and safety of a quadrivalent meningococcal tetanus toxoid-conjugate vaccine (MenACYW-TT) vs. a licensed quadrivalent meningococcal tetanus toxoid-conjugate vaccine in meningococcal vaccine-naïve and meningococcal C conjugate vaccine
![Immunogenicity and safety of a quadrivalent meningococcal tetanus toxoid-conjugate vaccine (MenACYW-TT) vs. a licensed quadrivalent meningococcal tetanus toxoid-conjugate vaccine in meningococcal vaccine-naïve and meningococcal C conjugate vaccine](https://static.cambridge.org/binary/version/id/urn:cambridge.org:id:binary:20210223191333153-0311:S0950268821000261:S0950268821000261_tab3.png?pub-status=live)
![](https://journals.lww.com/pidj/Documents/INF%20visual%20abstract_220-237_BaccariniOct2020.png)
Safety and Immunogenicity of a Quadrivalent Meningococcal Co : The Pediatric Infectious Disease Journal
NMR Assays for Estimating the O-Acetyl Content of Meningococcal Polysaccharide Serogroup A in Quadrivalent Conjugate Vaccine Formulation
![](https://www.futuremedicine.com/cms/10.2217/fmb-2018-0343/asset/images/medium/figure3.gif)
Immunogenicity and safety of meningococcal group A, C, W and Y tetanus toxoid conjugate vaccine: review of clinical and real-world evidence
![](https://cdn.hiv.uw.edu/doc/1128-1/recommendation-conjugate-quadrivalent-meningococcal-vaccine-persons-hiv.jpg)
Core Concepts - Immunizations in Adults - Basic HIV Primary Care - National HIV Curriculum
![](https://media.springernature.com/m685/springer-static/image/art%3A10.1038%2Fs41541-021-00409-1/MediaObjects/41541_2021_409_Fig1_HTML.png)
Combined effects of glycan chain length and linkage type on the immunogenicity of glycoconjugate vaccines
![](https://static.cambridge.org/binary/version/id/urn:cambridge.org:id:binary:20210420133028153-0386:S0950268821000698:S0950268821000698_fig2.png?pub-status=live)
Immunogenicity and safety of a quadrivalent meningococcal tetanus toxoid-conjugate vaccine administered concomitantly with other paediatric vaccines in toddlers: a phase III randomised study, Epidemiology & Infection
![](https://www.mdpi.com/vaccines/vaccines-08-00624/article_deploy/html/images/vaccines-08-00624-g003.png)
Vaccines, Free Full-Text
![](https://www.menquadfi.com/media/ems/conditions/vaccines/brands/menquadfi/site_images/desktop/2_0/safety-men-quadfi-vs-menveo-a-v-22-220330.gif)
Clinical Trials - Safety and Adverse Reactions MenQuadfi® (Meningococcal [Groups A, C, Y, W] Conjugate Vaccine)
![](https://static.cambridge.org/binary/version/id/urn:cambridge.org:id:binary:20210223191333153-0311:S0950268821000261:S0950268821000261_tab3.png?pub-status=live)
Immunogenicity and safety of a quadrivalent meningococcal tetanus toxoid-conjugate vaccine (MenACYW-TT) vs. a licensed quadrivalent meningococcal tetanus toxoid-conjugate vaccine in meningococcal vaccine-naïve and meningococcal C conjugate vaccine
![](https://www.thelancet.com/cms/attachment/94cb0973-abfc-49e4-bbbf-1fc57e578fbe/gr1_lrg.gif)
Safety and immunogenicity of a pentavalent meningococcal conjugate vaccine containing serogroups A, C, Y, W, and X in healthy adults: a phase 1, single-centre, double-blind, randomised, controlled study - The Lancet Infectious
![](https://media.springernature.com/m685/springer-static/image/art%3A10.1007%2Fs40121-023-00864-4/MediaObjects/40121_2023_864_Fig8_HTML.png)
Structured Benefit-Risk Assessment of a New Quadrivalent Meningococcal Conjugate Vaccine (MenACYW-TT) in Individuals Ages 12 Months and Older
![](https://www.tandfonline.com/cms/asset/1c025786-8797-4817-a7ba-ded5e6b0ab82/khvi_a_2099142_f0003_b.gif)
Full article: Immunogenicity and safety of MenACWY-TT, a quadrivalent meningococcal tetanus toxoid conjugate vaccine recently licensed in the United States for individuals ≥2 years of age